1. Home
  2. YSG vs AKBA Comparison

YSG vs AKBA Comparison

Compare YSG & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YSG

Yatsen Holding Limited

HOLD

Current Price

$4.16

Market Cap

889.0M

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.44

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YSG
AKBA
Founded
2016
2007
Country
China
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
889.0M
729.1M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
YSG
AKBA
Price
$4.16
$1.44
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$6.25
AVG Volume (30 Days)
133.1K
3.0M
Earning Date
02-24-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$571,300,568.00
$225,071,000.00
Revenue This Year
$28.96
$52.38
Revenue Next Year
$16.57
$22.45
P/E Ratio
N/A
N/A
Revenue Growth
22.59
32.49
52 Week Low
$3.12
$1.30
52 Week High
$11.57
$4.08

Technical Indicators

Market Signals
Indicator
YSG
AKBA
Relative Strength Index (RSI) 41.47 45.90
Support Level $4.11 $1.35
Resistance Level $4.62 $1.41
Average True Range (ATR) 0.30 0.08
MACD 0.06 0.01
Stochastic Oscillator 24.32 56.60

Price Performance

Historical Comparison
YSG
AKBA

About YSG Yatsen Holding Limited

Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: